Title:
GSK-3β INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2008/016123
Kind Code:
A1
Abstract:
Disclosed is a GSK-3β inhibitor comprising an oxadiazole compound or
a salt or prodrug thereof which is useful as a prophylactic/therapeutic agent
for a GSK-3β-related condition or disease. The GSK-3β inhibitor
comprises a compound represented by the formula (I) or a salt or prodrug thereof.
(I) wherein each symbol is as defined in the description.
Inventors:
ITOH FUMIO (JP)
KUNITOMO JUN (JP)
KOBAYASHI HIROMI (JP)
KIMURA EIJI (JP)
SAITOH MORIHISA (JP)
KAWAMOTO TOMOHIRO (JP)
IWASHITA HIROKI (JP)
MURASE KATSUHITO (JP)
KUNITOMO JUN (JP)
KOBAYASHI HIROMI (JP)
KIMURA EIJI (JP)
SAITOH MORIHISA (JP)
KAWAMOTO TOMOHIRO (JP)
IWASHITA HIROKI (JP)
MURASE KATSUHITO (JP)
Application Number:
PCT/JP2007/065203
Publication Date:
February 07, 2008
Filing Date:
August 02, 2007
Export Citation:
Assignee:
TAKEDA PHARMACEUTICAL (JP)
ITOH FUMIO (JP)
KUNITOMO JUN (JP)
KOBAYASHI HIROMI (JP)
KIMURA EIJI (JP)
SAITOH MORIHISA (JP)
KAWAMOTO TOMOHIRO (JP)
IWASHITA HIROKI (JP)
MURASE KATSUHITO (JP)
ITOH FUMIO (JP)
KUNITOMO JUN (JP)
KOBAYASHI HIROMI (JP)
KIMURA EIJI (JP)
SAITOH MORIHISA (JP)
KAWAMOTO TOMOHIRO (JP)
IWASHITA HIROKI (JP)
MURASE KATSUHITO (JP)
International Classes:
C07D413/04; A61K31/427; A61K31/428; A61K31/437; A61K31/4422; A61K31/4439; A61K31/444; A61K31/4709; A61K31/4725; A61K31/496; A61K31/519; A61K31/5377; A61K31/55; A61P1/04; A61P1/16; A61P3/00; A61P3/04; A61P3/06; A61P3/10; A61P9/00; A61P9/10; A61P9/12; A61P11/00; A61P11/06; A61P13/02; A61P17/06; A61P17/14; A61P19/02; A61P19/10; A61P21/04; A61P25/00; A61P25/02; A61P25/08; A61P25/14; A61P25/16; A61P25/18; A61P25/22; A61P25/24; A61P25/28; A61P27/02; A61P29/00; A61P31/04; A61P35/00; A61P37/08; A61P39/02; A61P43/00; C07D413/14; C07D417/04; C07D417/14; C07D471/04; C07D487/04; C07D491/048
Domestic Patent References:
| WO2006044860A2 | 2006-04-27 | |||
| WO2005111018A1 | 2005-11-24 | |||
| WO2005051942A1 | 2005-06-09 | |||
| WO2005051308A2 | 2005-06-09 | |||
| WO2005105780A2 | 2005-11-10 | |||
| WO2007071598A1 | 2007-06-28 | |||
| WO2005040157A2 | 2005-05-06 | |||
| WO2003101968A1 | 2003-12-11 | |||
| WO2004094388A2 | 2004-11-04 | |||
| WO2005023251A1 | 2005-03-17 | |||
| WO2000004014A1 | 2000-01-27 | |||
| WO2006069155A2 | 2006-06-29 |
Foreign References:
| JP2005298437A | 2005-10-27 | |||
| JP2004536782A | 2004-12-09 | |||
| JP2005530709A | 2005-10-13 | |||
| JP2004513882A | 2004-05-13 | |||
| JP2005194444A | 2005-07-21 | |||
| JPH0812579A | 1996-01-16 | |||
| JP2006513258A | 2006-04-20 | |||
| JP2006503062A | 2006-01-26 | |||
| JP2000514806A | 2000-11-07 | |||
| JP2000515136A | 2000-11-14 | |||
| JP2000514445A | 2000-10-31 | |||
| JP2006509840A | 2006-03-23 |
Other References:
NAERUM L. ET AL.: "Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors", BIOORG. MED. CHEM. LETT., vol. 12, no. 11, 2002, pages 1525 - 1528, XP003019916
CHEMICAL ABSTRACTS, 1984, Columbus, Ohio, US; abstract no. 101:16831, MASSONE G. ET AL.: "2,5-Diaryl-substituted 1,3,4-oxadiazoles: synthesis and preliminary pharmacological research" XP003019926
CHEMICAL ABSTRACTS, 2001, Columbus, Ohio, US; abstract no. 136:79264, RUSNAK D.W. ET AL.: "The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer" XP003019927
CHEMICAL ABSTRACTS, 1984, Columbus, Ohio, US; abstract no. 101:16831, MASSONE G. ET AL.: "2,5-Diaryl-substituted 1,3,4-oxadiazoles: synthesis and preliminary pharmacological research" XP003019926
CHEMICAL ABSTRACTS, 2001, Columbus, Ohio, US; abstract no. 136:79264, RUSNAK D.W. ET AL.: "The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer" XP003019927
Attorney, Agent or Firm:
TAKASHIMA, Hajime (1-1 Fushimimachi 4-chome,Chuo-ku, Osaka-sh, Osaka 44, JP)
Download PDF: